SHH and central nervous system neoplasm: Addressing these limitations will not only enhance our understanding of the SHH signalling pathway and its therapeutic implications in CNS tumours but also facilitate the development of more effective treatments that leverage cellular regulatory mechanisms and interactions with other molecular signalling pathways, ultimately improving clinical outcomes.